Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01592370 · ClinicalTrials.gov registry record · Phase 1

An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

A Phase 1 study of Multiple Myeloma and Hodgkin Lymphoma, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 1
Development phase
320
Enrollment target
20
Study locations

NCT01592370 is a Phase 1 study of Multiple Myeloma and Hodgkin Lymphoma that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 320 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (41% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01592370, a Phase 1 study of Multiple Myeloma and Hodgkin Lymphoma, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 1
Development phase
320 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to determine the side effects of treatment of the combination of nivolumab and daratumumab in participants with relapsed/refractory multiple myeloma.

Conditions Studied

Multiple Myeloma Hodgkin Lymphoma Non-Hodgkin's Lymphoma

Interventions

  • BIOLOGICAL Nivolumab
  • BIOLOGICAL Daratumumab
  • BIOLOGICAL Ipilimumab
  • DRUG Pomalidomide
  • BIOLOGICAL Lirilumab

Study Locations (20)

California

  • Local Institution - 0035 - Clovis
  • Division Of Hematology & Oncology Ctr. For Health Sciences - Los Angeles
  • Local Institution - 0012 - Los Angeles

Massachusetts

  • Dana-Farber Cancer Institute - Boston
  • Local Institution - 0009 - Boston
  • Local Institution - 0015 - Boston

Maryland

  • Local Institution - 0003 - Baltimore
  • The Sidney Kimmel Comprehensive Cancer Center - Baltimore

Michigan

  • Local Institution - 0011 - Ann Arbor
  • University Of Michigan Health System - Ann Arbor

Minnesota

  • Local Institution - 0002 - Rochester
  • Mayo Clinic - Rochester

Colorado

  • Local Institution - 0017 - Aurora

Connecticut

  • Local Institution - 013 - New Haven

Florida

  • Local Institution - 0023 - Orlando

Trial Details

FieldValue
Enrollment Target 320 participants
Start Date 2012-08-02
Est. Completion 2024-07-09
Phase Phase 1

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01592370

The ClinicalTrials.gov registry entry for NCT01592370 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 320 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (41% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Nivolumab is the first listed.

NCT01592370 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Massachusetts, Maryland.

Frequently Asked Questions

What is clinical trial NCT01592370 about?

NCT01592370 is a clinical study titled "An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma". The purpose of this study is to determine the side effects of treatment of the combination of nivolumab and daratumumab in participants with relapsed/refractory multiple myeloma.

What is the current status of trial NCT01592370?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 320 participants. The study started on 2012-08-02. Estimated completion is 2024-07-09.

What conditions does trial NCT01592370 study?

This clinical trial studies the following conditions: Multiple Myeloma, Hodgkin Lymphoma, Non-Hodgkin's Lymphoma.

What interventions are being tested in trial NCT01592370?

The interventions under investigation include: Nivolumab (BIOLOGICAL), Daratumumab (BIOLOGICAL), Ipilimumab (BIOLOGICAL), Pomalidomide (DRUG), Lirilumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT01592370?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01592370 being conducted?

This trial has 20 study locations across California, Colorado, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Hodgkin Lymphoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.